Last reviewed · How we verify
Sinovac PCV24
At a glance
| Generic name | Sinovac PCV24 |
|---|---|
| Sponsor | Sinovac Life Sciences Co., Ltd. |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Clinical Trial of PCV24 in Children Aged 2-17 Years (PHASE1)
- Clinical Trial of PCV24 in Infants Aged 2-23 Months (PHASE1)
- Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years (PHASE2)
- Clinical Trial of PCV24 in Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sinovac PCV24 CI brief — competitive landscape report
- Sinovac PCV24 updates RSS · CI watch RSS
- Sinovac Life Sciences Co., Ltd. portfolio CI